|
**Overview**: Von Willebrand Disease Panel**Introduction**: The Von Willebrand Disease Panel is a diagnostic tool designed for von Willebrand disease screening using plasma samples. In India, von Willebrand disease (vWD) is the most common inherited bleeding disorder (~1 percent prevalence, higher in certain communities), causing mucosal bleeding, menorrhagia, and post-surgical hemorrhage due to vWF deficiency/dysfunction. High morbidity from under-testing in rural/low-SES patients with recurrent epistaxis, heavy menses, or family bleeding history, limited coagulation labs, delayed desmopressin or vWF concentrate leading to severe bleeding or unnecessary transfusions. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs immunoassay for vWF antigen, vWF activity, factor VIII, ristocetin cofactor, and vWF multimers over 3â€"5 days with high accuracy, valuable for classifying vWD type (quantitative vs qualitative) and guiding therapy. This diagnostic falls under coagulation screening and targets patients with bleeding symptoms or family history, addressing accurate detection to inform desmopressin response or factor replacement. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise vWD profiling and reducing bleeding complications. Its plasma-based approach ensures reliable functional/multimer analysis.**Other Names**: vWD Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: vWF antigen/activity/ristocetin panel standard in bleeding disorder workup; in India, expanding in hemophilia centers.**Purpose**: The test assesses 5 parameters including vWF Antigen to guide von Willebrand disease screening, detect deficiency/dysfunction, inform therapy.**Test Parameters**: 1. vWF Antigen, 2. vWF Activity, 3. Factor VIII, 4. Ristocetin Cofactor, 5. vWF Multimers.**Pretest Condition**: No fasting required; patients should have bleeding symptoms.**Specimen**: 3 mL plasma in NaCit tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve coagulation factors, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on epistaxis, menorrhagia, family bleeding.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected vWD including hemorrhage, benefits of screening, and minimal discomfort from sampling.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique and interpret results within 3â€"5 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, anticoagulants can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Low vWF antigen/activity indicates vWD, necessitating specialist input.**Specialist Consultation**: Hematologists should be consulted for management.**Additional Supporting Tests**: Bleeding time, multimer analysis for confirmation.**Test Limitations**: Affected by acute phase; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Bleeding Disorder Studies India 2023. |
